XORTX Therapeutics (XRTX) Common Equity (2020 - 2026)

XORTX Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• Quarterly Common Equity fell 53.17% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 53.17% YoY) and the FY2025 annual result came in at $2.1 million, down 37.53% from the prior year.
• Common Equity was $1.3 million for Q1 2026 at XORTX Therapeutics, down from $2.1 million in the prior quarter.
• Across five years, Common Equity topped out at $10.6 million in Q1 2022 and bottomed at $1.3 million in Q1 2026.
• A 5-year average of $4.9 million and a median of $3.3 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity surged 155.01% — and 2024, when it plunged 72.5%.
• XORTX Therapeutics' Common Equity stood at $7.0 million in 2022, then sank by 33.44% to $4.6 million in 2023, then declined by 28.12% to $3.3 million in 2024, then tumbled by 37.53% to $2.1 million in 2025, then slumped by 38.41% to $1.3 million in 2026.
• Business Quant data shows XRTX's Common Equity at $1.3 million in Q1 2026, $2.1 million in Q4 2025, and $2.0 million in Q3 2025.